Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Phase 1Diagnosis: Solid Tumor/Phase INCT ID: NCT00585195
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID:
PF-02341066 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. This research study is the first time PF-02341066 will be given to people. PF-02341066 is taken by mouth daily.
Conducting Institutions: Dana-Farber Cancer Institute, Massachusetts General Hospital, Brigham and Women's Hospital, Beth-Israel Deaconess Medical Center
Overall PI: Jeffrey Clark, MD,
Massachusetts General Hospital
Site-responsible Investigators: Bruce Dezube, MD,
Beth Israel Deaconess Medical CenterGeoffrey Shapiro, MD, PhD,
Dana-Farber Cancer Institute
Contacts: Massachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100Beth-Israel Deaconess Medical Center:
Cancer Trials Call Center, 617-667-3060Dana-Farber Cancer Institute:
Andrew Wolanski, 617-632-6623,